Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
about
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsThe CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell functionIn vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.Differences in Activation of HIV-1 Replication by Superinfection With HIV-1 and HIV-2 in U1 Cells.Class 1-selective histone deacetylase inhibitors enhance HIV latency reversal while preserving the activity of HDAC isoforms necessary for maximal HIV gene expression.Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro.The latest evidence for possible HIV-1 curative strategies.Novel Latency Reversal Agents for HIV-1 Cure.Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T Cells.Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
P2860
Q28079455-98226B98-634F-47F7-9210-83BE6D035828Q33725916-88C27434-DCF2-4B09-BEFC-AA474F2358B5Q35942658-6E537787-C551-4409-B180-4B67778476B6Q37144949-A38F98BC-5226-48CF-A87E-93FAA1120D75Q37493633-05077085-A846-422E-8285-671F9E682AE9Q38725384-34F8BF2D-C3F2-4AF6-912D-DAACE61C4D1BQ39749215-E5A06159-CB54-42C0-970E-B07071176439Q40529337-FA61EFAD-524A-470B-88FB-9223898D8235Q47234362-8BDFB623-7BEF-4E0D-97BA-32CA8BFA1398Q49925023-BA17BC4E-15A6-42DF-85D4-8F2EF03ED31AQ50334467-76217C4B-CA3F-4068-B1A6-60B80EA21962Q52430553-D1792618-D8C0-4037-A114-030D1646FB1DQ52816327-20649F0A-1148-40CF-AED1-4EAE2103277FQ54224088-B3A79828-C8BC-472E-B7BE-C903C309D694Q56962083-019AF4CB-8E4D-42EA-99D7-DE2B7308329B
P2860
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Synergistic Activation of Late ...... e Inhibitors and Bryostatin-1.
@ast
Synergistic Activation of Late ...... e Inhibitors and Bryostatin-1.
@en
type
label
Synergistic Activation of Late ...... e Inhibitors and Bryostatin-1.
@ast
Synergistic Activation of Late ...... e Inhibitors and Bryostatin-1.
@en
prefLabel
Synergistic Activation of Late ...... e Inhibitors and Bryostatin-1.
@ast
Synergistic Activation of Late ...... e Inhibitors and Bryostatin-1.
@en
P2093
P2860
P50
P356
P1433
P1476
Synergistic Activation of Late ...... se Inhibitors and Bryostatin-1
@en
P2093
Maria Isabel Clemente
Maria Jesús Serramía
Santiago Moreno
P2860
P2888
P356
10.1038/SREP16445
P407
P577
2015-11-13T00:00:00Z